Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Cash & Equivalents (2022 - 2026)

Rallybio's Cash & Equivalents history spans 4 years, with the latest figure at $31.4 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 125.66% to $31.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.4 million, a 125.66% increase, with the full-year FY2025 number at $31.4 million, up 125.66% from a year prior.
  • Cash & Equivalents hit $31.4 million in Q4 2025 for Rallybio, down from $32.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RLYB hit a ceiling of $57.0 million in Q4 2022 and a floor of $9.4 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $25.8 million across 4 years, with a median of $24.5 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 57.0% in 2023 and later skyrocketed 125.66% in 2025.
  • Tracing RLYB's Cash & Equivalents over 4 years: stood at $57.0 million in 2022, then crashed by 57.0% to $24.5 million in 2023, then crashed by 43.24% to $13.9 million in 2024, then skyrocketed by 125.66% to $31.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for RLYB at $31.4 million in Q4 2025, $32.1 million in Q3 2025, and $9.4 million in Q2 2025.